![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Scandinavian Clinical Research AS, NO-2027 Kjeller, Norway;
* Betanien Medical Center, NO-0172 Oslo, Norway;
Helsetorget Medical Center, NO-2408 Elverum, Norway;
** Capturo AS, NO-2027 Kjeller, Norway; and
MATFORSK, Norwegian Food Research Institute, NO-1430 Ås, Norway
2To whom correspondence should be addressed. E-mail: j-m{at}scr.no.
After 12 mo in a randomized, double-blind, placebo-controlled trial of conjugated linoleic acid (CLA) supplementation (2 groups received CLA as part of a triglyceride or as the free fatty acid, and 1 group received olive oil as placebo), 134 of the 157 participants who concluded the study were included in an open study for another 12 mo. The goals of the extension study were to evaluate the safety [with clinical chemistry analyses and reported adverse events (AEs)] and assess the effects of CLA on body composition [body fat mass (BFM), lean body mass (LBM), bone mineral mass (BMM)], body weight, and BMI. All subjects were supplemented with 3.4g CLA/d in the triglyceride form. Circulating lipoprotein(a) and thrombocytes increased in all groups. There was no change in fasting blood glucose. Aspartate amino transferase, but not alanine amino transferase, increased significantly. Plasma total cholesterol and LDL cholesterol were reduced, whereas HDL cholesterol and triglycerides were unchanged. The AE rate decreased compared with the first 12 mo of the study. Body weight and BFM were reduced in the subjects administered the placebo during the initial 12 mo study (–1.6 ± 3.2 and –1.7 ± 2.8 kg, respectively). No fat or body weight changes occurred in the 2 groups given CLA during the initial 12 mo. LBM and BMM were not affected in any of the groups. Changes in body composition were not related to diet and/or training. In conclusion, this study shows that CLA supplementation for 24 mo in healthy, overweight adults was well tolerated. It confirms also that CLA decreases BFM in overweight humans, and may help maintain initial reductions in BFM and weight in the long term.
KEY WORDS: • conjugated linoleic acid • body composition • body mass index • weight reduction
This article has been cited by other articles:
|
|
 |
|
  T. Tsuzuki and Y. Kawakami Tumor angiogenesis suppression by {alpha}-eleostearic acid, a linolenic acid isomer with a conjugated triene system, via peroxisome proliferator-activated receptor {gamma} Carcinogenesis, April 1, 2008; 29(4): 797 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. N Close, D. A Schoeller, A. C Watras, and E. H Nora Conjugated linoleic acid supplementation alters the 6-mo change in fat oxidation during sleep Am. J. Clinical Nutrition, September 1, 2007; 86(3): 797 - 804. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Cruz-Hernandez, J. K. G. Kramer, J. J. Kennelly, D. R. Glimm, B. M. Sorensen, E. K. Okine, L. A. Goonewardene, and R. J. Weselake Evaluating the Conjugated Linoleic Acid and Trans 18:1 Isomers in Milk Fat of Dairy Cows Fed Increasing Amounts of Sunflower Oil and a Constant Level of Fish Oil J Dairy Sci, August 1, 2007; 90(8): 3786 - 3801. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Ip, S. O. McGee, P. A. Masso-Welch, C. Ip, X. Meng, L. Ou, and S. F. Shoemaker The t10,c12 isomer of conjugated linoleic acid stimulates mammary tumorigenesis in transgenic mice over-expressing erbB2 in the mammary epithelium Carcinogenesis, June 1, 2007; 28(6): 1269 - 1276. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L.-F. Liu, A. Purushotham, A. A. Wendel, and M. A. Belury Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice Am J Physiol Gastrointest Liver Physiol, June 1, 2007; 292(6): G1671 - G1682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. D Whigham, A. C Watras, and D. A Schoeller Efficacy of conjugated linoleic acid for reducing fat mass: a meta-analysis in humans Am. J. Clinical Nutrition, May 1, 2007; 85(5): 1203 - 1211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Steck, A. M. Chalecki, P. Miller, J. Conway, G. L. Austin, J. W. Hardin, C. D. Albright, and P. Thuillier Conjugated Linoleic Acid Supplementation for Twelve Weeks Increases Lean Body Mass in Obese Humans J. Nutr., May 1, 2007; 137(5): 1188 - 1193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Poole and C. E. McQueen Conjugated linoleic acid. Am. J. Health Syst. Pharm., November 1, 2006; 63(21): 2056 - 2062. [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Burr, C. G. Taylor, and H. A. Weiler Dietary Conjugated Linoleic Acid Does Not Adversely Affect Bone Mass in Obese fa/fa or Lean Zucker Rats. Experimental Biology and Medicine, November 1, 2006; 231(10): 1602 - 1609. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tsuzuki, Y. Kawakami, R. Abe, K. Nakagawa, K. Koba, J. Imamura, T. Iwata, I. Ikeda, and T. Miyazawa Conjugated Linolenic Acid Is Slowly Absorbed in Rat Intestine, but Quickly Converted to Conjugated Linoleic Acid J. Nutr., August 1, 2006; 136(8): 2153 - 2159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Porsgaard, X. Xu, and H. Mu The Form of Dietary Conjugated Linoleic Acid Does Not Influence Plasma and Liver Triacylglycerol Concentrations in Syrian Golden Hamsters J. Nutr., August 1, 2006; 136(8): 2201 - 2206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Poirier, J. S. Shapiro, R. J. Kim, and M. A. Lazar Nutritional Supplementation With trans-10, cis-12-Conjugated Linoleic Acid Induces Inflammation of White Adipose Tissue Diabetes, June 1, 2006; 55(6): 1634 - 1641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Larsen, S. Toubro, O. Gudmundsen, and A. Astrup Conjugated linoleic acid supplementation for 1 y does not prevent weight or body fat regain Am. J. Clinical Nutrition, March 1, 2006; 83(3): 606 - 612. [Abstract] [Full Text] [PDF]
|
|
